Par/Three Rivers Ribavirin ANDA Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
Launch of the Rebetol generic is "on the near-term horizon," Par CEO Tarriff says. Approval is contingent on resolution of labeling issues.